An observational study in Influenza, Human, sponsored by Cyril Barbezange. Enrolling by invitation at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-08.
Sponsored by Cyril Barbezange · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Influenza, Human with a site in Belgium — 4 open to participants now, 5 under way, 2 of them phase 3. Influenza, Human · Belgium.
Among the 106 studies in Influenza, Human with a site in Belgium, this one is one of 3 that started in 2023, is one of 9 observational ones, and was the 97th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →4 of the 106 studies in Influenza, Human with a site in Belgium are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Belgium, United States, Argentina and 36 more countries
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
UMC Utrecht · Sites in Belgium, United States, Australia and 26 more countries
Ages 28 days+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 35 · Phase 3 36 · Phase 4 8
First in 2003; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is below the median of 403 across 335 observational studies indexed under Influenza, Human.
Median enrollment 243 across the 97 interventional studies, 241 across the 9 observational. Of the 99 that completed or were terminated, 41 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 106 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Cyril Barbezange as lead sponsor.
Cyril Barbezange has 1 study filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
2 of the studies in Influenza, Human with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT03748069Universitaire Ziekenhuizen KU LeuvenInfluenza Associated Aspergillosis In-depth Investigation | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 106 studies in Influenza, Human with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The project aims at implementing a more pro-active surveillance of potential transmission of influenza viruses to humans (zoonotic transmission). Clinical surveillance of influenza in humans and avian species is well organized and has been operating for decades, but currently there is no pro-active systematic surveillance of potential transmission of animal (avian or swine) influenza viruses to humans, only follow-up of people showing clinical symptoms. People working with potentially infected animals have the highest risk. Moreover, they can represent the first steps in a pandemic: if the virus adapts to humans, infected workers could potentially spread the virus to other people.
Currently, highly pathogenic clade2.3.4.4b H5 avian influenza viruses are continuously circulating in wild birds in Belgium and the number of introduction in poultry farms has raised, increasing the contact opportunities with high viral concentrations. Several reports of suspected human infection have been made by different countries. In addition, the virus was detected in sick non-human mammals. The large circulation in wild birds thus represents an increase risk of spill-over to mammalian species, including humans, (by contact directly with wild birds, or via outbreaks in poultry). This increased opportunity for accidental spillover to new host species increases the chances for the avian virus to adapt to mammals, including humans.
Likewise, there have also been an increased number of human cases of swine influenza reported by several European countries. A pro-active surveillance aiming at also detecting asymptomatic infections would allow an early detection of transmission that could help to prevent a new pandemic.
As a piloting approach during this specific project, some dedicated sentinel networks among at-risk workers will be initiated: people in poultry farms involved with the management of outbreaks of highly pathogenic avian influenza; people working at bird (or more generally wild life) rehabilitation centres or poultry farms; veterinarians working in pig farms/slaughterhouses.
Workers or volunteers of one of the targeted groups within the sites that accept to take part in the study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
People involved in outbreak management, ranging from poultry farm owners and their family to inspectors through veterinarians and cullers/cleaners, will be invited to take part in the study at the earliest step possible after outbreak detection. Self sampling by nasopharyngeal swab will be requested every 2 days during 2 weeks.
Diagnostic Test: respiratory specimen · Diagnostic Test: serum
People working in poultry farms and in contact with animals will be invited to join the cohort. Self sampling by nasopharyngeal swab will be requested every 2 weeks for the whole duration of the study. anticipated: 15
Diagnostic Test: respiratory specimen
People working in wild bird/life rehabilitation centers and in contact with animals will be invited to join the cohort. Self sampling by nasopharyngeal swab will be requested every 2 weeks for the whole duration of the study. anticipated: 25
Diagnostic Test: respiratory specimen
Veterinarians working in the pig industry and in contact with animals will be invited to join the cohort. Self sampling by nasopharyngeal swab will be requested every 2 weeks for the whole duration of the study. anticipated: 15
Diagnostic Test: respiratory specimen
participants will perform self-sampling with a nasopharyngeal swab
participants will be invited to get a blood sample taken by a general practitioner or to perform a self sampling of capillary blood
Number of sentinel participants positive for a non-seasonal influenza virus
result of RT-qPCR test to detect and characterize non-influenza viruses
Time frame: every 2 weeks through study completion (December 2024)
Number of outbreak participants positive for a non-seasonal influenza virus
result of RT-qPCR test to detect and characterize non-influenza viruses
Time frame: every 2 days during 2 weeks after enrollment
Number of outbreak participants with seroconversion against a non-seasonal influenza virus
result of inhibition of haemagglutination or seroneutralisation assay
Time frame: at enrollment and about 4 weeks after
Started Sep 2023 (actual). Primary completion is estimated for Dec 2024, 15 months after the start.
Of 98 non-industry observational studies under Influenza, Human, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 92. This study's planned 15 months is below that.
Counting every sponsor, half of 135 studies reached it within 23 months; a quarter within 7 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.